First-line therapies include granulocyte colony-stimulating factor (G-CSF) for autoimmune neutropenia, rituximab for pemphigus nodularis and other autoantibody-mediated diseases, nutritional support, standard care for diabetes mellitus and autoimmune thyroid disease, and topical therapies for dermatitis [79]. Here, CSF3 is linked to dermatitis.